190 related articles for article (PubMed ID: 37185155)
1. Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma.
Zhang L; Åkerström T; Mollazadegan K; Beuschlein F; Pacak K; Skogseid B; Crona J
Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37185155
[TBL] [Abstract][Full Text] [Related]
2. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
Gagnon N; Mansour S; Bitton Y; Bourdeau I
Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
[TBL] [Abstract][Full Text] [Related]
3. Pheochromocytoma/paraganglioma-associated cardiomyopathy.
Szatko A; Glinicki P; Gietka-Czernel M
Front Endocrinol (Lausanne); 2023; 14():1204851. PubMed ID: 37522121
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma.
Lopez C; Bima C; Bollati M; Bioletto F; Procopio M; Arata S; Candela DG; Beccuti G; Ghigo E; Maccario M; Parasiliti-Caprino M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982228
[TBL] [Abstract][Full Text] [Related]
5. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
Gruber LM; Jasim S; Ducharme-Smith A; Weingarten T; Young WF; Bancos I
J Clin Endocrinol Metab; 2021 May; 106(6):e2393-e2401. PubMed ID: 33693908
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Cardiac Complications in Patients With Pheochromocytoma and Paraganglioma: A Retrospective Single-Center Study.
Zhao L; Meng X; Mei Q; Fan H; Liu Y; Zhou X; Zhu H; Zhang S
Front Endocrinol (Lausanne); 2022; 13():877341. PubMed ID: 35721724
[TBL] [Abstract][Full Text] [Related]
7. Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment.
Gosk-Przybyłek M; Doroszko A; Dobrowolski P; Warchoł-Celińska E; Harazny J; Bińczyk E; Szymanek K; Pęczkowska M; Kabat M; Toutounchi S; Gałązka Z; Górnicka B; Szaflik J; Januszewicz M; Klisiewicz A; Hoffman P; Lenders JWM; Eisenhofer G; Szaflik JP; Schmieder RE; Prejbisz A; Januszewicz A
J Hypertens; 2020 Aug; 38(8):1551-1558. PubMed ID: 32205562
[TBL] [Abstract][Full Text] [Related]
8. Response to Letter to the Editor regarding 'Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma'.
Zhang L; Åkerström T; Mollazadegan K; Beuschlein F; Pacak K; Skogseid B; Crona J
Endocr Relat Cancer; 2024 Jan; 31(1):. PubMed ID: 38031994
[No Abstract] [Full Text] [Related]
9. Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series.
Deljou A; Kohlenberg JD; Weingarten TN; Bancos I; Young WF; Schroeder DR; Martin DP; Sprung J
BMC Anesthesiol; 2018 Nov; 18(1):158. PubMed ID: 30400849
[TBL] [Abstract][Full Text] [Related]
10. Predictive Factors for Catecholamine-Induced Cardiomyopathy in Patients with Pheochromocytoma and Paraganglioma.
Wang Y; Yu X; Huang Y
Front Endocrinol (Lausanne); 2022; 13():853878. PubMed ID: 35355563
[TBL] [Abstract][Full Text] [Related]
11. [Clinical profile of pheochromocytoma and paraganglioma with normal plasma free metanephrines].
Liu L; Tian J; Wu K; Gao Y; Zhang Z; Zhang JQ; Guo XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 52(4):614-620. PubMed ID: 32773788
[TBL] [Abstract][Full Text] [Related]
12. Intrarenal hemodynamics and kidney function in pheochromocytoma and paraganglioma before and after surgical treatment.
Januszewicz M; Dobrowolski P; Januszewicz A; Warchoł-Celińska E; Jóźwik-Plebanek K; Motyl D; Kabat M; Pęczkowska M; Michałowska I; Ambroziak U; Toutounchi S; Gałązka Z; Courcelles L; Pappaccogli M; Eisenhofer G; Persu A; Lenders JWM; Kądziela J; Prejbisz A
Blood Press; 2021 Jun; 30(3):172-179. PubMed ID: 33586556
[TBL] [Abstract][Full Text] [Related]
13. Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases.
Kawashima A; Sone M; Inagaki N; Okamoto K; Tsuiki M; Izawa S; Otsuki M; Okamura S; Ichijo T; Katabami T; Takeda Y; Yoshimoto T; Naruse M; Tanabe A
Endocrine; 2021 Oct; 74(1):155-162. PubMed ID: 34272648
[TBL] [Abstract][Full Text] [Related]
14. Urinary Free Metanephrines for Diagnosis of Pheochromocytoma and Paraganglioma.
Ahn J; Park JY; Kim G; Jin SM; Hur KY; Lee SY; Kim JH
Endocrinol Metab (Seoul); 2021 Jun; 36(3):697-701. PubMed ID: 34107605
[TBL] [Abstract][Full Text] [Related]
15. Pheochromocytoma/paraganglioma crisis: case series from a tertiary referral center for pheochromocytomas and paragangliomas.
Meijs AC; Snel M; Corssmit EPM
Hormones (Athens); 2021 Jun; 20(2):395-403. PubMed ID: 33575936
[TBL] [Abstract][Full Text] [Related]
16. Pheochromocytoma- and paraganglioma-triggered Takotsubo syndrome.
Y-Hassan S; Falhammar H
Endocrine; 2019 Sep; 65(3):483-493. PubMed ID: 31399912
[TBL] [Abstract][Full Text] [Related]
17. Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes.
Cui Y; Ma X; Gao Y; Chang X; Chen S; Lu L; Tong A
Front Endocrinol (Lausanne); 2021; 12():762548. PubMed ID: 34899602
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamics in Patients With Pheochromocytoma or Paraganglioma Undergoing Non-neuroendocrine Operations.
Valencia Morales DJ; Laporta ML; Zec S; Yu K; Bancos I; Martin DP; Martin McGrew YN; Weingarten TN; Hanson AC; Sun J; Schroeder DR; Sprung J
J Surg Res; 2022 Sep; 277():189-199. PubMed ID: 35500514
[TBL] [Abstract][Full Text] [Related]
19. Risk of metastatic pheochromocytoma and paraganglioma in
Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
Naruse M; Satoh F; Tanabe A; Okamoto T; Ichihara A; Tsuiki M; Katabami T; Nomura M; Tanaka T; Matsuda T; Imai T; Yamada M; Harada T; Kawata N; Takekoshi K
Endocr J; 2018 Mar; 65(3):359-371. PubMed ID: 29353821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
